Armando Magrelli

Prof. Armando Magrelli

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Blood
Verified
Journal Article
Closed access
VFValerio Fulci
Valerio Fulci
SCSabina Chiaretti
Sabina Chiaretti
MGMarina Goldoni
Marina Goldoni
GAGianluca Azzalin
Gianluca Azzalin
NCNicoletta Carucci
Nicoletta Carucci
GMGiuseppe Macino
Giuseppe Macino
MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that modulate the expression of genes at the posttranscriptional level. These small molecules have been shown to be involved in cancer, apoptosis, and cell metabolism. In the present study we provide an informative profile of the expression of miRNAs in primary chronic lymphocytic leukemia (CLL) cells using 2 independent and quantitative methods: miRNA cloning and quantitative real-time–polymerase chain reaction (qRT-PCR) of mature miRNAs. Both approaches show that miR-21 and miR-155 are dramatically overexpressed in patients with CLL, although the corresponding genomic loci are not amplified. miR-150 and miR-92 are also significantly deregulated in patients with CLL. In addition, we detected a marked miR-15a and miR-16 decrease in about 11% of cases. Finally, we identified a set of miRNAs whose expression correlates with biologic parameters of prognostic relevance, particularly with the mutational status of the IgVH genes. In summary, the results of this study offer for the first time a comprehensive and quantitative profile of miRNA expression in CLL and their healthy counterpart, suggesting that miRNAs could play a primary role in the disease itself.

24 June 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DMDaniela Marazziti
Daniela Marazziti
EGElisabetta Golini
Elisabetta Golini
SMSilvia Mandillo
Silvia Mandillo
Armando MagrelliArmando Magrelli
Armando Magrelli
WWWalter Witke
Walter Witke
GTGlauco P. Tocchini-Valentini
Glauco P. Tocchini-Valentini
GPR37 is an orphan G protein-coupled receptor expressed in mammalian brain, and its insoluble aggregates are found in the brain samples of juvenile Parkinson's disease patients. We have produced aGpr37knock-out mouse strain and identified several phenotypic features that are similar to those reported for mutants of genes encoding components of synaptic dopamine vesicles. Our results reveal an unanticipated role of GPR37 in regulating substantia nigra-striatum dopaminergic signaling.Gpr37-/-mice are viable, with normal brain development and anatomy, but they exhibit reduced striatal dopamine content, enhanced amphetamine sensitivity, and specific deficits in motor behavior paradigms sensitive to nigrostriatal dysfunction. These functional alterations are not associated with any substantial loss of substantia nigra neurons or degeneration of striatal dopaminergic afferences, the main histological marks of Parkinson's disease. The inactivation of GPR37, in fact, has protective effects on substantia nigra neurons, causing resistance to treatment with the Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

1 July 2019 in Neuromuscular Disorders
Verified
Journal Article
Open access
MHMarion Haberkamp
Marion Haberkamp
JMJane Moseley
Jane Moseley
DADimitrios Athanasiou
Dimitrios Athanasiou
FAFernando de Andres-Trelles
Fernando de Andres-Trelles
AEAndré Elferink
André Elferink
Armando MagrelliArmando Magrelli
Armando Magrelli
Development of novel therapies for Duchenne muscular dystrophy (DMD) are driving the need for more efficient ways of detecting changes in disease- progression in DMD [1]. However, medicines' approval must be based on outcome measures that are acceptable from a regulatory perspective. In this article, European regulators provide an update on the recent regulatory consideration of a new endpoint (Stride Velocity 95th Centile (SV95C)) that could be used in therapeutic DMD trials. This new endpoint aims to quantify a patient's ambulation directly, reliably and continuously in a home environment with a wearable device.

28 October 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
ECElisabetta Caprini
Elisabetta Caprini
CCCristina Cristofoletti
Cristina Cristofoletti
DADiego Arcelli
Diego Arcelli
PFPaolo Fadda
Paolo Fadda
MCMauro Helmer Citterich
Mauro Helmer Citterich
GRGiandomenico Russo
Giandomenico Russo
In this study, we used single nucleotide polymorphism and comparative genomic hybridization array to study DNA copy number changes and loss of heterozygosity for 28 patients affected by Sézary syndrome (SS), a rare form of cutaneous T-cell lymphoma (CTCL). Our data identified, further confirming previous studies, recurrent losses of 17p13.2-p11.2 and 10p12.1-q26.3 occurring in 71% and 68% of cases, respectively; common gains were detected for 17p11.2-q25.3 (64%) and chromosome 8/8q (50%). Moreover, we identified novel genomic lesions recurring in >30% of tumors: loss of 9q13-q21.33 and gain of 10p15.3-10p12.2. Individual chromosomal aberrations did not show a significant correlation with prognosis; however, when more than three recurrent chromosomal alterations (gain or loss) were considered, a statistical association was observed using Kaplan-Meier survival analysis. Integrating mapping and transcriptional data, we were able to identify a total of 113 deregulated transcripts in aberrant chromosomal regions that included cancer-related genes such as members of the NF-κB pathway (BAG4, BTRC, NKIRAS2, PSMD3, and TRAF2) that might explain its constitutive activation in CTCL. Matching this list of genes with those discriminating patients with different survival times, we identify several common candidates that might exert critical roles in SS, such as BUB3 and PIP5K1B. Altogether, our study confirms and maps more precisely the regions of gain and loss and, combined to transcriptional profiles, suggests a novel set of genes of potential interest in SS. [Cancer Res 2009;69(21):8438–46]

1 July 2010 in Reproductive Toxicology
Verified
Journal Article
Closed access
Francesca MaranghiFrancesca Maranghi
Francesca Maranghi
SLStefano Lorenzetti
Stefano Lorenzetti
RTRoberta Tassinari
Roberta Tassinari
GMGabriele Moracci
Gabriele Moracci
VTValentina Tassinari
Valentina Tassinari
AMAlberto Mantovani
Alberto Mantovani

1 September 2009 in Translational Oncology
Verified
Journal Article
Open access
Armando MagrelliArmando Magrelli
Armando Magrelli
GAGianluca Azzalin
Gianluca Azzalin
MSMarco Salvatore
Marco Salvatore
MVMara Viganotti
Mara Viganotti
FTFabrizio Tosto
Fabrizio Tosto
DTDomenica Taruscio
Domenica Taruscio
Liver cancers in children are rare representing only 1.1% of malignancies, with an annual incidence rate of 1.5 cases per million. Hepatoblastoma and hepatocellular carcinomas are the most common malignancies of the liver occurring in young people aged 15 years or younger. Molecular basis of both tumors are still unclear, and common markers (i.e., CTNNB1, APC, IGF-2) are not always useful in the characterization of sporadic forms; in this respect, microRNA recently associated with carcinogenesis could play a pivotal role in their onset. CTNNB1 and APC were analyzed by sequencing, and IGF-2 promoter methylation status was assessed by methylation-specific polymerase chain reaction. MicroRNA expression was assayed by microarray and quantitative reverse transcription-polymerase chain reaction in hepatoblastoma samples. Although few genomic alterations were detected in ours samples, an altered expression of somemicroRNA in hepatoblastoma was observed. Unsupervised clustering shows that microRNA profile can distinguish tumor from nontumor tissues. Further analyses of microRNA contents in hepatoblastoma compared with hepatocellular carcinoma highlighted four upregulated microRNA (miR-214, miR-199a, miR-150 [P < .01], and miR-125a [P < .05]) and one downregulated microRNA (miR-148a [P < .01]). In conclusion, although our samples were poorly informative from a genetic point of view, they showed a peculiar microRNA expression pattern compared with nontumor tissues and hepatocellular carcinoma. MicroRNA could represent valid markers for the classification of pediatric liver tumors.